Fortis Healthcare Limited — Q4 FY25
Fortis Healthcare reported a strong Q4 FY25 with consolidated revenue of INR 2,007 crore (+12.5% YoY) and EBITDA margin of 21.7% (+40bps YoY).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY25
Hospital margin guidance of 20.5% for FY25
Management expects hospital EBITDA margin to reach 20.5% for the full year FY25, with a medium-term target of 25%.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY25
Diagnostics margin guidance of 21-22% for FY25
Agilus Diagnostics is expected to deliver adjusted EBITDA margin of 21-22% for FY25.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q3 FY25
Manesar greenfield to break even by Q1 FY26
The Manesar facility, currently at INR 5 crore monthly revenue, is expected to break even at INR 9 crore per month by Q1 FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1